We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Islet Autoantibody Screening Reveal Pediatric Type 1 Diabetes Risk

By LabMedica International staff writers
Posted on 17 Feb 2020
Type 1 diabetes (T1D) is a chronic progressive autoimmune disorder with complex polygenic susceptibility, usually associated with certain HLA alleles (IDDM1 locus). More...
Progression to T1D is typically marked by the presence of islet-specific autoantibodies in the serum. In humans, autoantibodies are present months to years before disease onset.

Public health screening for T1D in its pre-symptomatic stages may reduce disease severity and burden on a population level. Pre-symptomatic T1D increases the risk for developing clinical T1D in children aged two to five years, but can be identified via islet autoantibody screening. The rate of T1D development varies among individuals, possibly due to non-HLA genetic factors and/or environmental factors beyond the initial trigger.

A team of scientists specializing in diabetes and led by the Helmholtz Zentrum München (Munich-Neuherberg, Germany) conducted islet autoantibody screening using the blood samples from 90,632 children aged 1.75 to 5.99 years residing in Bavaria, Germany (median age, 3.1 years; 48.5% girls). Participants with at least two islet autoantibodies were diagnosed with pre-symptomatic T1D. The team established three stages of pre-symptomatic T1D, culminating in clinical T1D (stage 3).

The investigators identified pre-symptomatic T1D in 280 participants. Stage 1 occurred in 196 participants, stage 2 in 17 participants and stage 3 in 26 participants. During follow-up, those with pre-symptomatic T1D had a 24.9% cumulative risk and 9% annualized risk for reaching stage 3 T1D. There was a 28.7% cumulative risk and a 10.6% annualized risk for stage 2 and/or stage 3 T1D for those with stage 1 pre-symptomatic T1D at baseline. There were two cases of diabetic ketoacidosis in the cohort with pre-symptomatic T1D, according to the scientists, who noted that four children who did not have pre-symptomatic T1D at baseline went on to have clinical T1D.

Anette-Gabriele Ziegler, MD, a Professor and lead author of the study, said, “This sort of screening would reduce the number of acute and dangerous cases of type 1 diabetes that we would see. Care would start at a much earlier stage when the child is still feeling well. It gives time to learn about the disease, adjust to the likelihood of clinical disease whenever it occurs.” The study was published on January 28, 2020 in the journal JAMA.

Related Links:
Helmholtz Zentrum München


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.